There is no reason to panic, but researchers have advised people to stay cautious of Arcturus. High-risk groups, such as people older than 65 with underlying sickness, pregnant women, and people ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating ...

Arcturus has been described as having the usual Covid symptoms of a fever and cough, however infected people in India have also reported suffering from an "itchy" conjunctivitis or pinkeye ...

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...

Arcturus Therapeutics, based in San Diego, has proprietary enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) self-transcribing and replicating mRNA (STARR) technology, and (iii ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics (NASDAQ:ARCT) in the last three months. The table below summarizes ...

Arcturus is advancing its vaccine and rare disease pipeline with significant developments. The initiation of a BARDA-funded Phase 1 study for bird flu, along with ongoing studies in cystic ...

Nevertheless, the MHLW is an important milestone for the saRNA field and the Arcturus/CSL alliance ... vaccine technology will be available to people at risk for COVID-19.” ...

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154 ...

HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Cantor Fitzgerald reiterated an ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy recommendation. As of December 23, 2024, the average one-year price ...